Intellipharmaceutics International Inc. said its ongoing lawsuits with affiliates of Purdue Pharma LP have been stayed after Purdue filed for a bankruptcy stay.
Toronto-based Intellipharmaceutics was defending allegations that its pain relief drug Rexista infringed on patents owned by Purdue.
The patent infringement lawsuit is under a stay until March 2, 2020.
Purdue filed for bankruptcy protection in September after it reached a deal with state officials to settle its alleged involvement in the U.S. opioid epidemic.
The Stamford, Conn.-based maker of painkiller OxyContin said it will provide more than $10 billion in funding for life-saving opioid overdose reversal medications such as nalmefene and naloxone, which will be provided by a newly established entity called NewCo at zero to low cost, to help address the crisis.
